Likes	Subject	Older Newer
	I’m convinced that everyone has gone mad at		Sesh	01/27/23 4:42 AM
	The Pfizer vaccine that’s killing people all over		Sesh	01/25/23 7:30 AM
	It’s all in the patent filings for the		Sesh	01/25/23 1:40 AM
	So instead of doing the right thing here		Sesh	01/25/23 1:11 AM
	Oh and also despite numerous warnings from Russia		Sesh	01/25/23 1:06 AM
	Tony Blair the former PM of the UK		Sesh	01/25/23 12:52 AM
	So now because the market is full of		Sesh	01/25/23 12:45 AM
	You must be looking at a different chart		ssc	01/20/23 10:09 AM
	Perfect call.. lets see if this can get		structengr	01/18/23 2:44 PM
	Bott reversal in today.... (possibly tomorrow at latest).....		structengr	01/17/23 10:21 AM
	Mmm idk the bankers that went into their		Sesh	01/13/23 11:28 AM
	Sometimes companies are run by bad people.		ssc	01/13/23 9:41 AM
	I hope all the kids stinky Crohn’s farts		Sesh	01/13/23 9:25 AM
	I’m dumb for believing the market would actually		Sesh	01/13/23 9:24 AM
	This is a mirror of the incredible stupidity		Sesh	01/13/23 9:18 AM
	Delisted omg lol crazy! Guess I’ll be buying		Sesh	01/12/23 4:03 AM
	STAB: delisted from the Nasdaq to the OTC:		Renee	01/11/23 8:36 PM
	USDA approves “honey bee vaccine” to combat deadly		Sesh	01/06/23 4:51 PM
	China has developed a type of vaccine delivering		Sesh	01/06/23 4:21 PM
	Instead of salmonella outbreaks we’re gonna have vaccine-derived		Sesh	01/06/23 4:12 PM
	After conducting its own waste water investigation Canada		Sesh	01/06/23 4:01 PM
	Patents* connected to US patents		Sesh	01/06/23 5:00 AM
	There are 40,000 different variants of Covid-19 connected		Sesh	01/06/23 4:41 AM
	A phase 3 molecule for treating Crohn’s disease		Sesh	01/06/23 4:23 AM
	Severe Epidemic Enterovirus Respiratory Syndrome aka SEERS. If you		Sesh	01/06/23 4:06 AM
	They might be the only company with a		Sesh	01/03/23 2:08 PM
	There are 48+ different companies working with TLRs		Sesh	01/03/23 1:34 PM
	That’s why you’ve probably heard the term VAIDS		Sesh	01/03/23 1:08 PM
	Ten years this company has been developing their		Sesh	01/03/23 12:41 PM
	Dr. Sherri Tenpenny claims her medical research group		Sesh	01/03/23 12:36 PM
	Like how their treatment speeds the healing of		Sesh	01/03/23 3:52 AM
	Incidentally Statera also has a treatment that can		Sesh	01/03/23 2:25 AM
	The new AI system GPT-3 that’s been developed		Sesh	01/02/23 3:56 PM
	It’s an incredibly deadly game the market is		Sesh	01/02/23 1:27 PM
	Singapore and Beijing are kicking New York’s butt.		Sesh	01/01/23 1:41 PM
	I have warned everyone over and over what		Sesh	01/01/23 4:24 AM
	I have only one wish here, that the		Sesh	01/01/23 4:22 AM
	This isn’t a magic show. There’s only a handful		Sesh	01/01/23 4:17 AM
	I wonder if this will get up to		Sesh	12/30/22 3:17 PM
	This company was founded by immigrants who came		Sesh	12/29/22 6:17 AM
	The group and people that have destroyed this		Sesh	12/22/22 2:45 PM
	March 6th 2022 Dr. Richard Fleming testifies that		Sesh	12/22/22 2:20 PM
	So Statera is one of the least valuable		Sesh	12/22/22 1:51 PM
	JP Morgan is having their annual health care		Sesh	12/21/22 7:43 PM
	Nobody anywhere is immune from the effects of		Sesh	12/21/22 7:34 PM
	In general the market has no concern for		Sesh	12/21/22 7:20 PM
	There’s only two options for the market here.		Sesh	12/21/22 5:44 PM
	Guess who the most prolific breeders with the		Sesh	12/21/22 5:20 PM
	When a situation like what’s happening at the		Sesh	12/21/22 2:32 PM
	12 hours ago on msn.com Popular food dye		Sesh	12/21/22 12:23 AM
Likes	Subject	Older Newer

Older Newer

Sesh

01/27/23 4:42 AM

I’m convinced that everyone has gone mad at

Sesh

01/25/23 7:30 AM

The Pfizer vaccine that’s killing people all over

Sesh

01/25/23 1:40 AM

It’s all in the patent filings for the

Sesh

01/25/23 1:11 AM

So instead of doing the right thing here

Sesh

01/25/23 1:06 AM

Oh and also despite numerous warnings from Russia

Sesh

01/25/23 12:52 AM

Tony Blair the former PM of the UK

Sesh

01/25/23 12:45 AM

So now because the market is full of

ssc

01/20/23 10:09 AM

You must be looking at a different chart

structengr

01/18/23 2:44 PM

Perfect call.. lets see if this can get

structengr

01/17/23 10:21 AM

Bott reversal in today.... (possibly tomorrow at latest).....

Sesh

01/13/23 11:28 AM

Mmm idk the bankers that went into their

ssc

01/13/23 9:41 AM

Sometimes companies are run by bad people.

Sesh

01/13/23 9:25 AM

I hope all the kids stinky Crohn’s farts

Sesh

01/13/23 9:24 AM

I’m dumb for believing the market would actually

Sesh

01/13/23 9:18 AM

This is a mirror of the incredible stupidity

Sesh

01/12/23 4:03 AM

Delisted omg lol crazy! Guess I’ll be buying

Renee

01/11/23 8:36 PM

STAB: delisted from the Nasdaq to the OTC:

Sesh

01/06/23 4:51 PM

USDA approves “honey bee vaccine” to combat deadly

Sesh

01/06/23 4:21 PM

China has developed a type of vaccine delivering

Sesh

01/06/23 4:12 PM

Instead of salmonella outbreaks we’re gonna have vaccine-derived

Sesh

01/06/23 4:01 PM

After conducting its own waste water investigation Canada

Sesh

01/06/23 5:00 AM

Patents* connected to US patents

Sesh

01/06/23 4:41 AM

There are 40,000 different variants of Covid-19 connected

Sesh

01/06/23 4:23 AM

A phase 3 molecule for treating Crohn’s disease

Sesh

01/06/23 4:06 AM

Severe Epidemic Enterovirus Respiratory Syndrome aka SEERS. If you

Sesh

01/03/23 2:08 PM

They might be the only company with a

Sesh

01/03/23 1:34 PM

There are 48+ different companies working with TLRs

Sesh

01/03/23 1:08 PM

That’s why you’ve probably heard the term VAIDS

Sesh

01/03/23 12:41 PM

Ten years this company has been developing their

Sesh

01/03/23 12:36 PM

Dr. Sherri Tenpenny claims her medical research group

Sesh

01/03/23 3:52 AM

Like how their treatment speeds the healing of

Sesh

01/03/23 2:25 AM

Incidentally Statera also has a treatment that can

Sesh

01/02/23 3:56 PM

The new AI system GPT-3 that’s been developed

Sesh

01/02/23 1:27 PM

It’s an incredibly deadly game the market is

Sesh

01/01/23 1:41 PM

Singapore and Beijing are kicking New York’s butt.

Sesh

01/01/23 4:24 AM

I have warned everyone over and over what

Sesh

01/01/23 4:22 AM

I have only one wish here, that the

Sesh

01/01/23 4:17 AM

This isn’t a magic show. There’s only a handful

Sesh

12/30/22 3:17 PM

I wonder if this will get up to

Sesh

12/29/22 6:17 AM

This company was founded by immigrants who came

Sesh

12/22/22 2:45 PM

The group and people that have destroyed this

Sesh

12/22/22 2:20 PM

March 6th 2022 Dr. Richard Fleming testifies that

Sesh

12/22/22 1:51 PM

So Statera is one of the least valuable

Sesh

12/21/22 7:43 PM

JP Morgan is having their annual health care

Sesh

12/21/22 7:34 PM

Nobody anywhere is immune from the effects of

Sesh

12/21/22 7:20 PM

In general the market has no concern for

Sesh

12/21/22 5:44 PM

There’s only two options for the market here.

Sesh

12/21/22 5:20 PM

Guess who the most prolific breeders with the

Sesh

12/21/22 2:32 PM

When a situation like what’s happening at the

Sesh

12/21/22 12:23 AM

12 hours ago on msn.com Popular food dye

Older Newer

Statera BioPharma Inc. (STAB)

Followers	82	Posters	302
Posts (Today)	0	Posts (Total)	3493
Created	05/13/07	Type	Free
Moderators

PIPELINE https://www.staterabiopharma.com/pipeline/

Catalysts:
For years, the company has been developing its pipeline following three basic guidelines – a balanced approach, comprehensive and complex development as well as safety and foresight. By implementing those principles in its discovery, the company has created evolving therapeutics and continues to test and screen multiple cell types to ensure its drugs’ effectiveness.

In light of the company’s commitment, STAB recently reported major financial growth for 2021 with revenues of over $1.4 million – a 100% increase from the year-ago period. This massive increase was largely the result of the company’s acquisition of ImQuest Life Sciences, Inc. – a research and development company with a focus on cancer, inflammation and infectious disease treatments.

In terms of its expenses, STAB reported operating costs of over $31 million – a massive 191% increase from its year-ago period. Even though it is currently operating at a loss, CEO Michael Handley emphasized that STAB has “taken numerous steps to further develop its clinical stage pipeline.” As of now, it has invested in the expansion of clinical trial programs for its Crohn’s disease and COVID-19 drug treatments. For this reason, Handley believes the company is “well-positioned to achieve numerous milestones in 2022.”

The company seems poised for growth in the months ahead given that its all-stock deal to acquire ImQuest Life Sciences has previously provided STAB with the assets necessary to advance its internal drug development program. By integrating ImQuest BioSciences – the drug development department of ImQuest Life Sciences – into STAB’s existing drug development operations, the company can now offer a direct evaluation of all vaccines, biologics and pharmaceuticals in preclinical development.

In this way, STAB could capitalize on ImQuest BioSciences and its ability to achieve its mission of developing new immune therapies targeting cancers, infectious diseases and autoimmune disorders. This, in turn, will allow the company to develop a competitive advantage over other players in the industry.

As of now, STAB is developing a number of drug treatments covering several widespread diseases. Currently in its phase 2 trial, the company’s lead investigational drug candidate – STAT-201 – is developed for the treatment of pediatric patients with Crohn’s disease. After the FDA granted STAT-201 Orphan Drug Designation for the treatment of Crohn’s Disease in pediatric patients, STAB intends to initiate its Phase 3 clinical trials in the coming months. Given that Crohn’s disease affects an estimated 3 million US adults on an annual basis, the upside potential for this drug is looking promising.

The company is also capitalizing on the increase in demand for treatments of acute and post-acute COVID-19. Currently in phase 1 clinical trials, STAT-205 has the potential to treat these infections by modulating immune system functions and decreasing inflammatory responses affiliated with SARS-CoV-2 viral infections.

STAB is in prime position to achieve a breakthrough in its current studies given the proceeds from its latest direct offering. Handley has previously emphasized the company’s plans to “use proceeds from the direct offering to start the enrollment of patients in Q2 – in addition to including patients with acute COVID-19 infection in the company’s STAT-205 study”.

Recently, STAB announced it was granted approval by the Central Institutional Review Board to begin the Phase 3 clinical trial for STAT-201 in the treatment of pediatric Crohn’s Disease. Now that the sites are being selected, the company plans to include at least 165 patients in the trial – which is expected to begin as soon as Q2. As it initiates this trial, STAB could be among the best pharma stocks to buy this week.

Pancreatic cancer:
Statera is developing STAT-401 as an adjunct to standard of care therapy to extend the duration of disease remission in patients with pancreatic cancer. The U.S. Food and Drug Administration (FDA) granted STAT-401 Orphan Drug Designation for the disease. In August 2021, the company received feedback following a Type C meeting with the U.S. regulators regarding the STAT-401 clinical development program. The Company has established an advisory panel of oncology experts, and now expects to initiate a Phase 1b/2 clinical trial during the first half of 2022.

Michael K. Handley, President and CEO of Statera Biopharma, stated, “Pancreatic cancer remains a devastating disease despite the tremendous advances in cancer research. The American Cancer Society predicts that it could become the second-leading cause of cancer-related death behind lung cancer. We are harnessing our deep understanding of immune modulation to develop STAT-401 to help address this high need cancer population. With our advisory panel now in place, we look forward to advancing our clinical program and bringing hope to the patients and their families fighting this dreaded disease.

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA

for Investigational Treatment of Long-Haul COVID-19

The Company expects to conclude enrollment during the third quarter and report topline results in the fourth quarter.

https://ir.staterabiopharma.com/news-releases/news-release-details/correction-statera-biopharma-submits-phase-1-clinical-trial

Most Liked Posts
(Last 30 Days)

No Liked Posts in the last 30 Days

Volume:
Day Range:
Last Trade Time:

Quotes:

IHub:

Quotes:

IHub:

Statera BioPharma Inc. (STAB)

Most Liked Posts
(Last 30 Days)

Detailed Quote

Detailed Quote

STAB Latest News

More STAB News

Most Liked Posts
(Last 30 Days)

Quotes:

IHub:

Quotes:

IHub:

Latest Posts

Statera BioPharma Inc. (STAB)

Most Liked Posts (Last 30 Days)

STAB Latest News

Most Liked Posts (Last 30 Days)

Most Liked Posts
(Last 30 Days)

Most Liked Posts
(Last 30 Days)